GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer
Adding the anti-angiogenic antibody bevacizumab to chemotherapy lengthened survival by almost four months in recurrent or metastatic cervical cancer, the first targeted drug to improve survival in a gynaecological cancer.
Overview
Phase 3 factorial trial of 452 patients with recurrent, persistent or metastatic cervical cancer randomised to cisplatin-paclitaxel or topotecan-paclitaxel, with or without bevacizumab.
Median overall survival was 17.0 versus 13.3 months with bevacizumab (hazard ratio 0.71) and response 48 versus 36 percent; topotecan-paclitaxel was not superior to cisplatin-paclitaxel. Fistula occurred in about 6 percent of bevacizumab patients, mostly after prior radiotherapy.
- Median overall survival 17.0 vs 13.3 months; hazard ratio 0.71.
- Objective response 48 percent vs 36 percent.
Platinum-paclitaxel with bevacizumab became the first-line standard for advanced cervical cancer and remains the backbone to which pembrolizumab is added.
- Gastrointestinal and genitourinary fistulas in irradiated patients.
- Hypertension and thromboembolism increased.
Similar pages
not linked directly; found by shared links- Key paperHearing improvement after bevacizumab in patients with neurofibromatosis type 2
- Key paperKEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperEMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperinnovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
- Key paperSUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
- TrialBAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Shares Recurrent or metastatic cervical cancer, Bevacizumab.
- TrialA Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Shares Recurrent or metastatic cervical cancer, Bevacizumab.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc
Shares Recurrent or metastatic cervical cancer, Bevacizumab.